▶ 調査レポート

シロリムスのグローバル市場(~2027):カテーテル装置、リンパ管平滑筋腫症(LAM)、臓器移植拒絶反応、シロリムスコーティングバルーン

• 英文タイトル:Sirolimus Market Research Report by Application, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Sirolimus Market Research Report by Application, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「シロリムスのグローバル市場(~2027):カテーテル装置、リンパ管平滑筋腫症(LAM)、臓器移植拒絶反応、シロリムスコーティングバルーン」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2305D046
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、233ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社は、世界のシロリムス市場規模が2021年に417.61百万ドル、2022年には451.84百万ドルに達し、更に年平均8.37%成長して2027年には676.60百万ドルまで拡大すると予測しています。当調査資料は、シロリムスの世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、用途別分析(カテーテル装置、リンパ管平滑筋腫症(LAM)、臓器移植拒絶反応、シロリムスコーティングバルーン)、流通チャネル別分析(病院薬局、オンライン薬局、小売薬局)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの構成でまとめております。また、当書には、Aadi Bioscience, Inc.、Alkermes plc、Aurisco Pharmaceutical Co., Ltd.、Beijing THTD Pharmaceutical Technology Co., Ltd.、Cadila Healthcare Ltd、Chongqing Daxin Pharmaceutical Co., Ltd.、Chunghwa Chemical Synthesis & Biotech Co. Ltd.、Concept Medical, Inc.などの企業情報が含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界のシロリムス市場規模:用途別
- カテーテル装置における市場規模
- リンパ管平滑筋腫症(LAM)における市場規模
- 臓器移植拒絶反応における市場規模
- シロリムスコーティングバルーンにおける市場規模
・世界のシロリムス市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
・世界のシロリムス市場規模:地域別
- 南北アメリカのシロリムス市場規模
アメリカのシロリムス市場規模
カナダのシロリムス市場規模
ブラジルのシロリムス市場規模
...
- アジア太平洋のシロリムス市場規模
日本のシロリムス市場規模
中国のシロリムス市場規模
インドのシロリムス市場規模
韓国のシロリムス市場規模
台湾のシロリムス市場規模
...
- ヨーロッパ/中東/アフリカのシロリムス市場規模
イギリスのシロリムス市場規模
ドイツのシロリムス市場規模
フランスのシロリムス市場規模
ロシアのシロリムス市場規模
...
- その他地域のシロリムス市場規模
・競争状況
・企業情報

The Global Sirolimus Market size was estimated at USD 417.61 million in 2021 and expected to reach USD 451.84 million in 2022, and is projected to grow at a CAGR 8.37% to reach USD 676.60 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Sirolimus to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Application, the market was studied across Catheter Devices, Lymphangioleiomyomatosis(LAM), Organ Transplant Rejection, and Sirolimus Coated Balloons.

Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Sirolimus market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Sirolimus Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Sirolimus Market, including Aadi Bioscience, Inc., Alkermes plc, Aurisco Pharmaceutical Co., Ltd., Beijing THTD Pharmaceutical Technology Co., Ltd., Cadila Healthcare Ltd, Chongqing Daxin Pharmaceutical Co., Ltd., Chunghwa Chemical Synthesis & Biotech Co. Ltd., Concept Medical, Inc., Concord Biotech Limited, Cordis Corporation, Euticals Inc., Fujian Kerui Pharmaceutical Co., Ltd., Glenmark Pharmaceuticals Limited, Hangzhou Jinlan Pharm-Drugs Technology Co., Ltd., Intas Pharmaceuticals Ltd, M.A. Med Alliance SA, Pfizer Inc., Sandoz International GmbH, Shandong Octagon Chemicals Limited, Stentys, Tiefenbacher API + Ingredients GmbH & Co. KG, TIEFENBACHER GROUP, Torrent Pharmaceuticals Ltd., and Zhejiang Hisun Pharmaceutical Co. Ltd.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Sirolimus Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Sirolimus Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Sirolimus Market?
4. What is the competitive strategic window for opportunities in the Global Sirolimus Market?
5. What are the technology trends and regulatory frameworks in the Global Sirolimus Market?
6. What is the market share of the leading vendors in the Global Sirolimus Market?
7. What modes and strategic moves are considered suitable for entering the Global Sirolimus Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing transplantation rates with incidence of lifestyle-related diseases
5.1.1.2. Increasing improvement of healthcare infrastructure
5.1.1.3. Rising availability of promising pipeline for different indications
5.1.2. Restraints
5.1.2.1. Probable adverse effects of the compound
5.1.3. Opportunities
5.1.3.1. Technological advancements in organ transplantation globally
5.1.3.2. Surge in investments to reduce the side effects of the compound
5.1.4. Challenges
5.1.4.1. Preference for generic drug variants among patients
5.2. Cumulative Impact of COVID-19

6. Sirolimus Market, by Application
6.1. Introduction
6.2. Catheter Devices
6.3. Lymphangioleiomyomatosis(LAM)
6.4. Organ Transplant Rejection
6.5. Sirolimus Coated Balloons

7. Sirolimus Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies

8. Americas Sirolimus Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Sirolimus Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Sirolimus Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Aadi Bioscience, Inc.
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Alkermes plc
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Aurisco Pharmaceutical Co., Ltd.
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Beijing THTD Pharmaceutical Technology Co., Ltd.
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Cadila Healthcare Ltd
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Chongqing Daxin Pharmaceutical Co., Ltd.
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Chunghwa Chemical Synthesis & Biotech Co. Ltd.
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Concept Medical, Inc.
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Concord Biotech Limited
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Cordis Corporation
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Euticals Inc.
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Fujian Kerui Pharmaceutical Co., Ltd.
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Glenmark Pharmaceuticals Limited
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Hangzhou Jinlan Pharm-Drugs Technology Co., Ltd.
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Intas Pharmaceuticals Ltd
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. M.A. Med Alliance SA
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Pfizer Inc.
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Sandoz International GmbH
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Shandong Octagon Chemicals Limited
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Stentys
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services
12.21. Tiefenbacher API + Ingredients GmbH & Co. KG
12.21.1. Business Overview
12.21.2. Key Executives
12.21.3. Product & Services
12.22. TIEFENBACHER GROUP
12.22.1. Business Overview
12.22.2. Key Executives
12.22.3. Product & Services
12.23. Torrent Pharmaceuticals Ltd.
12.23.1. Business Overview
12.23.2. Key Executives
12.23.3. Product & Services
12.24. Zhejiang Hisun Pharmaceutical Co. Ltd
12.24.1. Business Overview
12.24.2. Key Executives
12.24.3. Product & Services

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing